首页> 外文期刊>The British Journal of Nutrition >Impact of serum 25-hydroxyvitamin D on cardiac prognosis in Chinese patients with heart failure
【24h】

Impact of serum 25-hydroxyvitamin D on cardiac prognosis in Chinese patients with heart failure

机译:血清25-羟基羟胞素D对中国心力衰竭患者心脏预后的影响

获取原文
获取原文并翻译 | 示例
           

摘要

There is growing evidence that suggests the association of vitamin D status with the development and progression of heart failure (HF). The objective of the present study is to assess the impact of concentration of serum 25-hydroxyvitamin D (25(OH)D) on cardiac prognosis in patients with HF. Between 1 January 2015 and 31 December 2016, we consecutively recruited patients with HF. Patients were followed prospectively for a median duration of 1 year. Serum concentration of 25(OH)D was measured with competitive chemiluminescent immunoassay. The endpoints were cardiac events, including CVD death and rehospitalisation for worsening HF. Univariate and multivariable adjustments were performed with Cox proportional-hazard regression analyses. The 25(OH)D concentration was obtained in 343 patients with a median value of 17·4 (interquartile range 12·6–23·4) ng/ml. There were 102 cardiac events, including forty-three deaths and fifty-nine rehospitalisations. Multivariate Cox hazard analysis found that the serum concentration 25(OH)D was independently associated with cardiac events (hazard ratio 0·93, 95 % CI 0·88, 0·97) and CVD mortality (hazard ratio 0·83; 95 % CI 0·77, 0·89) after adjustment for confounding factors. We divided the HF patients into four groups according to the 25(OH)D quartiles. Kaplan–Meier analysis found that the patients with lower serum 25(OH)D concentration had a higher risk of cardiac events or CVD mortality than those with high serum 25(OH)D concentration (log-rank test P 0·001 and P = 0·032). Decreased serum concentrations of 25(OH)D were associated with cardiac prognosis and CVD mortality in a Chinese population with HF independent of other baseline HF markers.
机译:越来越多的证据表明维生素D的结合与心力衰竭(HF)的开发和进展相关。本研究的目的是评估血清25-羟基维胺D(25(OH)D)对HF患者心脏预后的影响。 2015年1月1日至2016年12月31日之间,我们连续招募了HF患者。患者令人医随着1年的中位数持续时间。用竞争性化学发光免疫测定法测量血清浓度为25(OH)D.终点是心脏事件,包括用于恶化HF的CVD死亡和再培养。使用Cox比例危害回归分析进行单变量和多变量调节。在343名中值17·4(12·6-23·4)Ng / ml的患者中获得25(OH)D浓度。有102例心脏事件,包括四十三名死亡和五十九次再生。多变量Cox危险分析发现,血清浓度25(OH)D与心脏事件(危害比0·93,95%CI 0·88,0·97)和CVD死亡率(危险比0·83; 95%)独立相关CI 0·77,0·89)调整混杂因素后。我们将HF患者分成四组,根据25(OH)D四分位数。 Kaplan-Meier分析发现,血清中血清25(OH)D浓度的患者具有比具有高血清25(OH)D浓度的心脏事件或CVD死亡率的风险较高(对数级试验P& 0·001和p = 0·032)。降低25(OH)D的血清浓度与中国人群中的心脏预后和CVD死亡率有关,与其他基线HF标记无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号